Second U.S. Patent Issued for Safety Shot’s JW-700 Which Boosts Effectiveness of Minoxidil (Rogaine®) in $1.5 Billion Hair Growth Market
US 11,766,392 for JW-700, a topical treatment designed to improve minoxidil’s efficacy, marking a significant milestone in the development of treatments for androgenetic alopecia, or hair loss.
- US 11,766,392 for JW-700, a topical treatment designed to improve minoxidil’s efficacy, marking a significant milestone in the development of treatments for androgenetic alopecia, or hair loss.
- This is the second U.S. patent issued for JW-700 this year and adds to the growing global IP estate for Safety Shots Legacy products.
- Minoxidil is a widely used for the treatment of hair loss sold under brand names including Rogaine® and Hair Regrowth for Men®.
- This issued patent discloses composition and methods for inducing the expression of sulfotransferases in hair follicles and expands patent protection on JW-700’s new formulation.